BR0012387A - Composição para tratamento de distúrbios de secreção externa - Google Patents

Composição para tratamento de distúrbios de secreção externa

Info

Publication number
BR0012387A
BR0012387A BR0012387-0A BR0012387A BR0012387A BR 0012387 A BR0012387 A BR 0012387A BR 0012387 A BR0012387 A BR 0012387A BR 0012387 A BR0012387 A BR 0012387A
Authority
BR
Brazil
Prior art keywords
composition
treatment
disorders
external
secretion disorders
Prior art date
Application number
BR0012387-0A
Other languages
English (en)
Other versions
BRPI0012387B1 (pt
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR0012387A publication Critical patent/BR0012387A/pt
Publication of BRPI0012387B1 publication Critical patent/BRPI0012387B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "COMPOSIçãO PARA TRATAMENTO DE DISTúRBIOS DE SECREçãO EXTERNA". A presente invenção divulga uma composição para tratamento de distúrbios de secreção externa, compreendendo como ingrediente ativo um derivado de ácido graxo. A composição da presente invenção é útil no tratamento de pelo menos uma condição doentia selecionada de hipolacrimação, incluindo o distúrbio da secreção lacrimal basal, a síndrome do olho seco, a hipossalivação e a síndrome da boca seca.
BRPI0012387A 1999-07-14 2000-07-13 uso 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e2, 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina f2a-metil éster, 11-dehidroxi-13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e1 e 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e1 na indução de secreção lacrimal em um paciente com distúrbios envolvendo hipossecreção lacrimal BRPI0012387B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14362799P 1999-07-14 1999-07-14
PCT/JP2000/004696 WO2001005388A2 (en) 1999-07-14 2000-07-13 Use of a fatty derivative for the treatment of external secretiondisorders

Publications (2)

Publication Number Publication Date
BR0012387A true BR0012387A (pt) 2002-03-26
BRPI0012387B1 BRPI0012387B1 (pt) 2016-11-08

Family

ID=22504885

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0012387A BRPI0012387B1 (pt) 1999-07-14 2000-07-13 uso 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e2, 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina f2a-metil éster, 11-dehidroxi-13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e1 e 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e1 na indução de secreção lacrimal em um paciente com distúrbios envolvendo hipossecreção lacrimal

Country Status (25)

Country Link
US (3) US6566398B1 (pt)
EP (1) EP1223925B1 (pt)
JP (2) JP4167828B2 (pt)
KR (1) KR100750553B1 (pt)
CN (4) CN100548977C (pt)
AR (2) AR029381A1 (pt)
AT (1) ATE344027T1 (pt)
AU (1) AU779936B2 (pt)
BR (1) BRPI0012387B1 (pt)
CA (1) CA2377661C (pt)
CZ (1) CZ303958B6 (pt)
DE (1) DE60031710T2 (pt)
DK (1) DK1223925T3 (pt)
ES (1) ES2273706T3 (pt)
HK (1) HK1048443B (pt)
HU (1) HU229318B1 (pt)
IL (2) IL147440A0 (pt)
MX (1) MXPA02000437A (pt)
NO (1) NO323908B1 (pt)
PT (1) PT1223925E (pt)
RU (1) RU2264816C2 (pt)
TR (1) TR200200065T2 (pt)
TW (1) TWI225398B (pt)
WO (1) WO2001005388A2 (pt)
ZA (1) ZA200109726B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
WO2003105823A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US20040185075A1 (en) 2003-01-31 2004-09-23 Maria Dalko Use of at least one (dihydro)jasmonic acid derivative for treating dry skin
FR2850571B1 (fr) * 2003-01-31 2006-07-07 Oreal Utilisation d'un derive d'acide(dihydro) jasmonique pour le traitement des peaux seches
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP4249185B2 (ja) 2003-10-06 2009-04-02 株式会社オフテクス 涙液異常の治療のための眼科用組成物
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
MX2007000208A (es) * 2004-07-01 2007-08-07 Schepens Eye Res Inst Composiciones y metodos para tratar trastornos y condiciones del ojo.
DK1841433T3 (da) * 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
ATE489955T1 (de) * 2005-03-04 2010-12-15 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
NZ570190A (en) 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
JP2010519177A (ja) * 2007-02-27 2010-06-03 スキャンポ・アーゲー ミトコンドリアを保護するための組成物および方法
US9161909B2 (en) 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
WO2012068247A1 (en) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
RU2648474C2 (ru) * 2011-08-05 2018-03-26 Сукампо Аг Способ лечения шизофрении
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US8996137B2 (en) 2013-04-19 2015-03-31 Oculeve, Inc. Nasal stimulation devices and methods
KR20170074926A (ko) * 2014-10-22 2017-06-30 오큘레브, 인크. 안구 건조증을 치료하기 위한 자극 장치 및 방법
WO2017192572A1 (en) 2016-05-02 2017-11-09 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
JP7300446B2 (ja) 2018-04-26 2023-06-29 ライオン株式会社 外分泌促進剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
JPH07103096B2 (ja) * 1987-01-28 1995-11-08 株式会社上野製薬応用研究所 プロスタグランジンｄ類およびそれを含む鎮静・睡眠剤
DE3711164A1 (de) 1987-04-02 1988-10-20 Zeiss Carl Fa Steckelementeinrichtung zur halterung von bauteilen in stapeln
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
JPS63277604A (ja) * 1987-05-11 1988-11-15 Showa Denko Kk α−リノレン酸含有化粧料
JPH0692305B2 (ja) * 1987-05-15 1994-11-16 株式会社上野製薬応用研究所 体温上昇剤
ATE108330T1 (de) 1987-09-18 1994-07-15 R Tech Ueno Ltd Hypotensive okulare mittel.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
WO1990001323A1 (en) * 1988-08-12 1990-02-22 Bernstein Joel E Method and composition for treating and preventing dry skin disorders
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW249226B (pt) * 1990-04-04 1995-06-11 Aderk Ueno Kk
JPH07100655B2 (ja) * 1990-04-04 1995-11-01 株式会社アールテック・ウエノ 白内障処置剤
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
JPH07113012B2 (ja) * 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
ATE141794T1 (de) * 1991-03-14 1996-09-15 R Tech Ueno Ltd Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen
US5369127A (en) 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
WO2000038690A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
DK1841433T3 (da) * 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
ATE489955T1 (de) * 2005-03-04 2010-12-15 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten

Also Published As

Publication number Publication date
IL147440A0 (en) 2002-08-14
ZA200109726B (en) 2002-08-30
CN101829120A (zh) 2010-09-15
IL147440A (en) 2008-11-03
KR20020060149A (ko) 2002-07-16
CN101829120B (zh) 2013-09-18
US6566398B1 (en) 2003-05-20
NO20020133D0 (no) 2002-01-11
DK1223925T3 (da) 2007-03-19
WO2001005388A3 (en) 2002-05-10
RU2264816C2 (ru) 2005-11-27
CN101695495A (zh) 2010-04-21
US7396946B2 (en) 2008-07-08
JP2009007360A (ja) 2009-01-15
US20030171438A1 (en) 2003-09-11
HU229318B1 (hu) 2013-10-28
HUP0202400A3 (en) 2005-02-28
NO20020133L (no) 2002-03-13
NO323908B1 (no) 2007-07-16
AU5853300A (en) 2001-02-05
CA2377661A1 (en) 2001-01-25
CZ2002133A3 (cs) 2002-06-12
WO2001005388A2 (en) 2001-01-25
TR200200065T2 (tr) 2002-10-21
JP4167828B2 (ja) 2008-10-22
CN1915971A (zh) 2007-02-21
BRPI0012387B1 (pt) 2016-11-08
EP1223925A2 (en) 2002-07-24
DE60031710D1 (de) 2006-12-14
MXPA02000437A (es) 2004-05-21
HUP0202400A2 (hu) 2002-11-28
AR074465A2 (es) 2011-01-19
CN1399548A (zh) 2003-02-26
TWI225398B (en) 2004-12-21
CZ303958B6 (cs) 2013-07-17
HK1048443A1 (en) 2003-04-04
CA2377661C (en) 2012-05-08
DE60031710T2 (de) 2007-09-06
US20050090556A1 (en) 2005-04-28
EP1223925B1 (en) 2006-11-02
JP5052423B2 (ja) 2012-10-17
ES2273706T3 (es) 2007-05-16
PT1223925E (pt) 2007-01-31
ATE344027T1 (de) 2006-11-15
HK1048443B (zh) 2007-06-08
KR100750553B1 (ko) 2007-08-20
CN100548977C (zh) 2009-10-14
JP2003504397A (ja) 2003-02-04
AR029381A1 (es) 2003-06-25
AU779936B2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
BR0012387A (pt) Composição para tratamento de distúrbios de secreção externa
BR0015392A (pt) Lipoxina a4 e seus análogos para o tratamento de olho ressecado
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
CO5611138A2 (es) Composicion de ziprasidona y controles sinteticos
TR199900255T2 (xx) Muskarinik antagonistleri
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
ES2176432T3 (es) Tratamiento de isquemia cerebral y lesion cerebral mediante un agente neuroprotector.
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
DE69830512D1 (de) Heilmittel für neurodegenerative krankheiten
ES2227684T3 (es) Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco.
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
BR0012696A (pt) Composição oftálmica
DK0868909T3 (da) Opthalmisk bæreropløsning
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
WO2001030380A3 (en) Methods and compositions for treatment of keratoconus using protease inhibitors
WO2003105781A3 (en) OPHTHALMIC COMPOSITIONS FOR TREATING EYE HYPERTENSION
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
WO2002079235A3 (en) Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
BR0115077A (pt) Métodos e composições para o tratamento de doenças dos olhos
WO2002100836A3 (en) Compounds, compositions and methods for modulating beta-amyloid production
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/11/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.